Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures

Leukemia. 2024 Jun;38(6):1423-1426. doi: 10.1038/s41375-024-02243-5. Epub 2024 Apr 9.

Authors

Saurabh Zanwar¹, Morie A Gertz¹, Eli Muchtar¹, Francis K Buadi¹, Taxiarchis Kourelis¹, Wilson Gonsalves¹, Ronald S Go¹, Suzanne Hayman¹, Prashant Kapoor¹, Moritz Binder¹, Joselle Cook¹, David Dingli¹, Nelson Leung¹, Yi Lin¹, Rahma Warsame¹, Amie Fonder¹, Miriam Hobbs¹, Yi Lisa Hwa¹, Robert A Kyle¹, S Vincent Rajkumar¹, Shaji Kumar¹, Angela Dispenzieri²

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, US.
² Division of Hematology, Mayo Clinic, Rochester, MN, US. dispenzieri.angela@mayo.edu.

No abstract available

Publication types

Letter

MeSH terms

Aged
Antibodies, Monoclonal* / administration & dosage
Antibodies, Monoclonal* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Bortezomib* / administration & dosage
Bortezomib* / therapeutic use
Cyclophosphamide* / administration & dosage
Dexamethasone* / administration & dosage
Dexamethasone* / therapeutic use
Female
Humans
Immunoglobulin Light-chain Amyloidosis* / drug therapy
Immunoglobulin Light-chain Amyloidosis* / mortality
Male
Middle Aged
Treatment Failure

Substances

daratumumab
Bortezomib
Dexamethasone
Cyclophosphamide
Antibodies, Monoclonal